SCHEMBL1551981

SCHEMBL1551981

O=[N+]([O-])c1ccc(O)cc1Cl

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.64
MAPK1 P28482 1/20 0.64
CA1 P00915 1/20 0.54
CA2 P00918 1/20 0.54
MMP1 P03956 1/20 0.54
MMP2 P08253 1/20 0.54
MMP9 P14780 1/20 0.54
MMP8 P22894 1/20 0.54
MMP13 P45452 1/20 0.54
CYP3A4 P08684 2/20 0.52
ALDH1A1 P00352 1/20 0.52
F2 P00734 3/20 0.50
PRSS1 P07477 3/20 0.50
PRSS2 P07478 3/20 0.50
PRSS3 P35030 3/20 0.50
TDP1 Q9NUW8 1/20 0.50
LMNA P02545 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP2D6 P10635 1/20 0.49
MAPT P10636 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30923019 1.00 TSHR (0.64) TSHRMAPK1CA1CA2MMP1
SCHEMBL16712984 0.85 TSHR (0.56) TSHRMAPK1CA1CA2MMP1
SCHEMBL545300 0.83 VCAM1 (0.61) TSHRMAPK1CYP3A4ALDH1A1TDP1
SCHEMBL9362733 0.81 TSHR (0.51) TSHRMAPK1CA1CA2MMP1
SCHEMBL5857928 0.81 PDE7A (0.72) TSHRMAPK1CA1CA2MMP1
SCHEMBL29577003 0.80 TSHR (0.56) TSHRMAPK1CYP3A4ALDH1A1NPSR1
SCHEMBL213758 0.80 TSHR (0.56) TSHRMAPK1CYP3A4ALDH1A1NPSR1
SCHEMBL68980 0.78 GPR35 (0.67) TSHRMAPK1CYP3A4ALDH1A1TDP1
SCHEMBL29398960 0.78 TSHR (1.00) TSHRMAPK1CA1CA2MMP1
SCHEMBL29479746 0.78 GPR35 (0.67) TSHRMAPK1CYP3A4ALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 308 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025120654-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF TIVOZANIB HYDROCHLORIDE HYDRATE NATCO PHARMA LIMITED (IN) 2025-06-12 WO claimed
CN-118702085-A Method for regulating specific surface area of carbon material 三明学院 2024-09-27 CN claimed
CN-113683511-A Synthesis method of 2-chloro-4-trifluoromethylphenyl-4 '-nitro-3' -ethoxy phenyl ether 广东立威化工有限公司 2021-11-23 CN claimed
CN-109912424-B Method for hydrolyzing nitroaniline substances into phenol 浙江大学 2020-08-07 CN claimed
CN-111377865-A Preparation method of high-purity lenvatinib 北京启慧生物医药有限公司 2020-07-07 CN claimed
CN-109776498-B Preparation method of cilostazol 浙江永宁药业股份有限公司 2020-04-07 CN claimed
CN-109776498-A A kind of preparation method of Cilostazol 浙江永宁药业股份有限公司 2019-05-21 CN claimed
CN-105859559-A Production method of 3-ethoxy-4-nitrophenol 盐城工学院 2016-08-17 CN claimed
JP-8019095-B2 1996-02-28 JP claimed
EP-0302874-B1 INDOLOQUINONE COMPOUNDS SPECKAMP, Willem Nico (NL) 1992-12-02 EP claimed
EP-0302874-A1 INDOLOQUINONE COMPOUNDS. SPECKAMP WILLEM NICO (NL) 1989-02-15 EP claimed
WO-1987006227-A2 INDOLOQUINONE COMPOUNDS JOUHAR AKBAR JAN (GB) 1987-10-22 WO claimed
WO-2026087442-A1 AMINO-IMIDAZOLE ANTIBACTERIAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2026-04-30 WO disclosed
EP-4083031-B1 QUINOLINE COMPOUND AND APPLICATION THEREOF AS FGFR4 KINASE INHIBITOR SKYRUN PHARMA CO LTD (CN) 2026-04-22 EP disclosed
US-12570672-B2 Macrocyclic compounds and methods of use AMGEN INC. 2026-03-10 US disclosed
US-20250304599-A1 MACROCYCLIC COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2025-10-02 US disclosed
EP-0001734-A2 Imide groups containing polymers, processes for their preparation and their uses for making various objects RHONE-POULENC INDUSTRIES (FR) 1979-05-02 EP disclosed
US-4102924-A REACTING ACYLAMINO-ARYLS WITH HALO-ARYLS BAYER AKTIENGESELLSCHAFT (DE) 1978-07-25 US disclosed
US-4059627-A HYDROGENATION OF CHLORINATED NITRO AROMATIC, NOBLE METAL CATALYST, THIOETHER BAYER AKTIENGESELLSCHAFT (DT) 1977-11-22 US disclosed
US-4020084-A Cyclic aminals of aromatic aldehydes BAYER AKTIENGESELLSCHAFT (DT) 1977-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12570672-B2 Macrocyclic compounds and methods of use KRAS, NRAS, BRAF TSHR 1229/4885MAPK1 378/4885CA1 1784/4885
US-20250304599-A1 MACROCYCLIC COMPOUNDS AND METHODS OF USE KRAS, NRAS, HRAS TSHR 2922/4885MAPK1 670/4885CA1 2977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.